| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 126 | 136 | 102 | 105 | 118 | 119 | 81 | 100 | 114 | 131 | 150 | 173 | 164 | 176 | 123 | 61 | 65 | 160 | 151 | 151 | 136 | 167 | 163 | 248 | 166 | 198 | 176 | 250 | 197 | 244 |
| Expenses | 101 | 110 | 76 | 88 | 94 | 96 | 60 | 82 | 91 | 107 | 114 | 130 | 119 | 128 | 94 | 65 | 65 | 146 | 130 | 126 | 109 | 139 | 133 | 212 | 131 | 165 | 140 | 207 | 157 | 194 |
| EBITDA | 24 | 27 | 26 | 16 | 24 | 23 | 21 | 18 | 22 | 25 | 35 | 42 | 46 | 48 | 29 | -4 | 0 | 14 | 21 | 25 | 27 | 29 | 31 | 35 | 35 | 33 | 35 | 42 | 40 | 50 |
| Operating Profit % | 19 % | 19 % | 25 % | 15 % | 20 % | 19 % | 25 % | 15 % | 19 % | 18 % | 23 % | 24 % | 27 % | 27 % | 22 % | -7 % | -1 % | 9 % | 12 % | 16 % | 19 % | 17 % | 18 % | 14 % | 20 % | 16 % | 19 % | 16 % | 20 % | 20 % |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 | 4 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 | 6 |
| Profit Before Tax | 16 | 19 | 19 | 8 | 15 | 14 | 13 | 9 | 14 | 16 | 27 | 34 | 33 | 35 | 16 | -16 | -13 | 1 | 7 | 11 | 13 | 15 | 17 | 22 | 22 | 20 | 22 | 29 | 24 | 34 |
| Tax | 9 | 9 | 9 | -5 | 8 | 5 | 5 | 2 | 7 | 5 | 5 | 11 | 9 | 12 | 7 | -23 | 0 | 3 | 3 | 4 | 3 | 3 | 5 | 5 | 5 | 5 | 4 | 8 | 4 | 9 |
| Net Profit | 7 | 10 | 9 | 13 | 8 | 10 | 8 | 6 | 7 | 11 | 21 | 23 | 24 | 23 | 9 | 6 | -13 | -2 | 4 | 6 | 9 | 12 | 12 | 17 | 17 | 14 | 18 | 20 | 21 | 25 |
| EPS in ₹ | 0.85 | 1.19 | 1.11 | 1.57 | 0.92 | 1.17 | 0.90 | 0.76 | 0.83 | 1.30 | 2.53 | 2.73 | 2.78 | 2.72 | 1.07 | 0.73 | -1.51 | -0.24 | 0.44 | 0.73 | 1.10 | 1.39 | 1.36 | 2.04 | 1.95 | 1.67 | 2.15 | 2.40 | 2.31 | 2.84 |
SMS Pharmaceuticals
SMS Pharmaceuticals
319.20
-0.40
(-0.13%)
Market Cap
₹2,989.37 Cr
PE Ratio
31.49
Volume
14,25,984.00
Day High - Low
₹325.75 - ₹311.60
52W High-Low
₹335.00 - ₹176.05
Key Fundamentals
Market Cap
2,989.37 Cr
EPS
8.16
PB Ratio
3.64
Book Value
77.88
EBITDA
145.20
Dividend Yield
0.13 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.50
Actual
Company News
View All News
SMS Pharmaceuticals announced that its associate company VKT Pharma has received US FDA approval for reformulated Ranitidine tablets in 150mg and 300mg strengths, marking the re-entry of this acid-reducing medication into the US market after a five-year absence. The approval follows extensive safety testing and manufacturing improvements that address previous concerns regarding NDMA impurity formation, and is expected to increase patient access to this important medication.
SMS Pharmaceuticals Reports 80% PAT Growth in Q2 FY26, Driven by Backward IntegrationNov 13, 2025
SMS Pharmaceuticals delivered its highest-ever quarterly PAT of INR 25.3 crores with 80% year-on-year growth, supported by 23% revenue growth to INR 242.4 crores and EBITDA margins expanding to 20%. The strong performance was driven by backward integration projects worth INR 150 crores over 12-18 months, improved product mix optimization, and stabilized operations across key intermediates, with the company maintaining its FY26 targets of 20% growth and 20% EBITDA margin.
SMS Pharmaceuticals Limited reported strong quarterly results with PAT growing 80% YoY to ₹25.32 crore, marking the highest quarterly profit on record. Revenue from operations increased 23% YoY to ₹242.43 crore, supported by higher volumes and market share gains across key APIs. Gross margins expanded 30% YoY due to backward integration initiatives. EBITDA margins improved to 20% in Q2FY26, up 54% YoY, aided by backward integration and operating leverage. For H1FY26, revenue reached ₹438.48 crore (21% YoY growth) with PAT at ₹45.80 crore (50% YoY growth). The company's ₹280 crore capacity expansion program remains on track for completion by November 2026. Management maintains guidance of 20% revenue growth and 20% EBITDA margins for FY26. Operating cash flows remained strong at ₹42.32 crore in H1FY26, supporting ongoing capex investments.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,831.60 | #1 4,39,462.19 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 79.43 | |
6,477.00 | 1,71,944.00 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 49.62 | |
3,720.60 | 1,25,922.01 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 53.11 | |
1,531.30 | 1,23,691.38 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 50.63 | |
1,258.80 | 1,05,061.18 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 57.24 | |
2,082.20 | 95,105.43 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 65.07 | |
942.50 | 94,837.55 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 44.36 | |
2,251.00 | 92,911.94 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 38.76 | |
1,226.70 | 71,246.94 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 63.81 | |
5,685.00 | 67,972.70 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 53.82 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
10.55 %
Net Income Growth
36.99 %
Cash Flow Change
63.03 %
ROE
14.94 %
ROCE
5.02 %
EBITDA Margin (Avg.)
8.55 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 |
| Fixed Assets | 370 | 291 | 279 | 281 | 281 | 457 | 438 | 412 | 437 | 533 |
| Current Assets | 248 | 157 | 169 | 208 | 219 | 309 | 377 | 411 | 534 | 555 |
| Capital Work in Progress | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 |
| Investments | 0 | 29 | 28 | 27 | 26 | 27 | 22 | 11 | 11 | 12 |
| Other Assets | 272 | 166 | 187 | 232 | 260 | 321 | 389 | 424 | 556 | 573 |
| Total Liabilities | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 |
| Current Liabilities | 200 | 147 | 122 | 143 | 145 | 195 | 197 | 255 | 332 | 324 |
| Non Current Liabilities | 162 | 91 | 97 | 94 | 115 | 206 | 193 | 164 | 166 | 189 |
| Total Equity | 294 | 255 | 285 | 322 | 348 | 411 | 470 | 461 | 536 | 640 |
| Reserve & Surplus | 285 | 246 | 276 | 314 | 340 | 402 | 462 | 452 | 499 | 615 |
| Share Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Cash Flow
| Cash Flow | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -9 | 1 | 0 | 2 | -5 | 31 | 6 | -39 | 29 | 5 |
| Investing Activities | -97 | -39 | -17 | -35 | -43 | -152 | -27 | -30 | -52 | -123 |
| Operating Activities | 61 | 74 | 32 | 50 | 40 | 90 | 45 | 23 | 50 | 82 |
| Financing Activities | 27 | -33 | -15 | -13 | -2 | 92 | -12 | -32 | 31 | 47 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 67.29 % | 67.29 % | 67.29 % | 67.29 % | 67.29 % | 64.17 % | 64.17 % | 64.17 % | 64.29 % | 64.32 % | 64.32 % | 64.32 % | 64.67 % | 64.67 % | 64.67 % | 64.67 % | 66.26 % | 66.26 % | 68.07 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.60 % | 0.59 % | 0.17 % | 0.17 % | 0.52 % | 0.31 % | 0.08 % | 0.03 % | 0.28 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.98 % | 2.13 % | 2.55 % | 2.55 % | 2.43 % | 3.03 % | 2.88 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 26.92 % | 26.87 % | 26.23 % | 26.72 % | 26.38 % | 29.65 % | 28.84 % | 28.82 % | 29.00 % | 29.04 % | 29.08 % | 29.22 % | 27.93 % | 27.81 % | 27.04 % | 27.38 % | 26.35 % | 25.89 % | 24.02 % |
| Others | 5.79 % | 5.84 % | 6.47 % | 5.99 % | 6.33 % | 6.18 % | 6.98 % | 7.00 % | 6.70 % | 6.64 % | 6.01 % | 5.88 % | 5.25 % | 5.22 % | 5.23 % | 5.09 % | 4.87 % | 4.78 % | 4.76 % |
| No of Share Holders | 19,878 | 25,601 | 24,608 | 24,959 | 27,516 | 26,638 | 26,491 | 26,526 | 25,537 | 24,653 | 25,246 | 25,341 | 30,140 | 31,780 | 33,136 | 34,973 | 35,332 | 33,652 | 34,157 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.2 | 0.25 | 0.25 | 0.25 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 |
| Dividend Yield (%) | 0.00 | 0.27 | 0.4 | 0.93 | 0.2 | 0.32 | 0.53 | 0.17 | 0.19 | 0.13 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 24 Sept 2021 |  Dividend | ₹ 0.30 /share | 22 Sept 2021 | 167.60 | 157.70 |
| 23 Sept 2022 | Dividend | ₹ 0.30 /share | 22 Sept 2022 | 84.35 | 89.80 |
| 22 Sept 2023 | Dividend | ₹ 0.30 /share | 22 Sept 2023 | 84.40 | 121.50 |
| 06 Mar 2024 |  Extraordinary General Meeting | NA | 06 Mar 2024 | 146.45 | 181.90 |
| 23 Sept 2024 | Dividend | ₹ 0.40 /share | 23 Sept 2024 | 209.90 | 368.65 |
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 312.55 | 351.20 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 294.60 | 305.90 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 205.15 | 200.02 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 262.50 | 270.37 |
| 09 Aug 2025 | Quarterly Result Announcement | NA | 09 Aug 2025 | 228.91 | 223.95 |
| 22 Sept 2025 | Dividend | ₹ 0.40 /share | 22 Sept 2025 | 270.37 | 292.50 |
| 29 Sept 2025 | Annual General Meeting | NA | 29 Sept 2025 | 223.95 | 251.68 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 286.20 | 288.80 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call TranscriptNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 12, 2025
Nov 12, 2025Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Nov 11, 2025
Nov 11, 2025Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Nov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 10, 2025
Nov 10, 2025Statement Of Deviation Or Variation For The Quarter Ended September 30 2025Nov 08, 2025
Nov 08, 2025Financial Results For The Quarter Ended 30Th September 2025Nov 08, 2025
Nov 08, 2025Board Meeting Outcome for Outcome Of Board Meeting For Financial ResultsNov 08, 2025
Nov 08, 2025Intimation Of Receipt Of Trading Approval From Stock ExchangesNov 07, 2025
Nov 07, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011Nov 06, 2025
Nov 06, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 06, 2025
Nov 06, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Report On Transfer Requests Of Physical Shares Re-Lodged Under The Special WindowNov 05, 2025
Nov 05, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 04, 2025
Nov 04, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended 30Th September 2025Nov 03, 2025
Nov 03, 2025Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Oct 16, 2025
Oct 16, 2025Report On Transfer Requests Of Physical Shares Re-Lodged Under The Special WindowOct 10, 2025
Oct 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 10, 2025
Oct 10, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 29, 2025
Sep 29, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 29, 2025
Sep 29, 2025Closure of Trading WindowSep 27, 2025
Sep 27, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Sep 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Sep 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Sep 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Sep 13, 2025Clarification On Volume/Price MovementSep 12, 2025
Sep 12, 2025Clarification sought from SMS Pharmaceuticals LtdSep 12, 2025
Sep 12, 2025Conversion Of 5000000 Warrants Into Equity SharesSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Conversion of SecuritiesSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 08, 2025
Sep 08, 2025Dispatch Of Letter With Web-Link To Annual ReportSep 06, 2025
Sep 06, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 06, 2025
Sep 06, 2025Reg. 34 (1) Annual Report.Sep 06, 2025
Sep 06, 2025Notice Of 37Th Annual General Meeting And Annual Report For The FY 2024-25Sep 06, 2025
Sep 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 26, 2025
Aug 26, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Aug 25, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Aug 22, 2025
Aug 22, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 22, 2025
Aug 22, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 22, 2025
Aug 22, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 22, 2025
Aug 22, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Aug 22, 2025
Aug 22, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 14, 2025
Aug 14, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Quant Healthcare Fund Direct - Growth | 6.53% | 43932 | 1.12% | 1.39% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.06% | 2 | 0.01% | 0.01% | |
| Quant Small Cap Fund Direct Plan-Growth | 0.17% | 0 | 0.02% | 0.02% |
Technical Indicators
RSI(14)
Neutral 67.05
ATR(14)
Less Volatile 14.53
STOCH(9,6)
Neutral 45.80
STOCH RSI(14)
Overbought 95.37
MACD(12,26)
Bullish 3.23
ADX(14)
Strong Trend 31.39
UO(9)
Bearish 56.25
ROC(12)
Uptrend And Accelerating 10.87
WillR(14)
Neutral -24.35
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
